Research programme: siRNA therapeutics - Abeona Therapeutics
Latest Information Update: 24 May 2018
At a glance
- Originator Access Pharmaceuticals
- Developer Abeona Therapeutics
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 May 2018 Discontinued for Cancer in USA (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (PO)
- 04 Feb 2010 Early research in Cancer in USA (PO)